• 2-D08: Mapping SUMO Transfer in Cell Models

  2026-08-31

  2-D08, also known as 2’,3’,4’-trihydroxyflavone, is a selective probe for the substrate-transfer step of sumoylation. This article develops an assay-centered framework connecting topoisomerase I sumoylation inhibition with the mechanistic SUMO–mitophagy findings reported in bronchopulmonary dysplasia models.

• Halazone and Sodium Current Inactivation in Frog Nerves

  2026-08-30

  The reference study used halazone and related chemical probes to test whether specific amino acid residues control sodium-current inactivation in voltage-clamped frog nerve fibers. Its results weaken the case for a critical methionine residue and instead support a tentative role for chemically modified membrane lipids, while also illustrating how oxidant exposure can reshape channel kinetics without simply destroying the preparation.

• ORM2–ZG16 Autophagy Axis in Pancreatic Fibrosis

  2026-08-29

  A 2026 Pancreatology study identifies ORM2 as an endogenous inhibitor of chronic pancreatitis-associated fibrosis and links its activity to ZG16-dependent control of autophagy in pancreatic stellate cells. The work combines pancreas-specific AAV perturbation, cell-based fibrosis models, autophagy flux assays, and protein-interaction analyses to establish a mechanistic ORM2–ZG16 axis.

• Glutamine–STAT3 Control of PD-L1 in Pancreatic Cancer

  2026-08-29

  A pre-proof study in Genes & Diseases identifies glutamine abundance as a regulator of PD-L1 in pancreatic cancer through STAT3-dependent protein stabilization. The findings connect nutrient homeostasis, ubiquitination control, mTOR signaling, and tumor-cell proliferation, while suggesting experimental routes for separating PD-L1 transcription from post-translational regulation.

• High-Content Screening of Schistosome Stem Cells

  2026-08-28

  Perera, Chioni, and Walker developed a quantitative high-content platform that measures somatic neoblast proliferation in developmentally advanced liver-stage Schistosoma mansoni schistosomula. Screening 280 stem cell-focused compounds produced prioritized molecules that disrupted parasite development and stem cell proliferation, providing a more informative route to anti-schistosomal lead discovery than morphology or motility alone.

• Concanavalin A Blocks Coronaviruses via Conserved N-Glycans

  2026-08-28

  The reference study identifies concanavalin A (ConA) as a broad coronavirus entry inhibitor that binds conserved high-mannose N-glycans near the spike S2′ cleavage site rather than variable receptor-binding epitopes. By combining fusion, pseudovirus, authentic-virus, biochemical, and mouse experiments, the authors connect glycan recognition to impaired spike activation and highlight a mechanistic framework for broad-spectrum antiviral design.

• LY2886721: Reproducible BACE1 Assay Design

  2026-08-27

  This scenario-driven guide explains how LY2886721 (SKU A8465) can support controlled BACE1 inhibition and amyloid beta reduction in cellular and translational Alzheimer’s disease research. It covers assay interpretation, DMSO formulation, concentration selection, controls, and practical product-selection criteria.

• Phosphatase Inhibitor Cocktail: Practical Workflow

  2026-08-27

  Preserve labile phosphorylation signals with a dual-component workflow built for immunoblotting, immunoprecipitation, kinase assays, and phosphoproteomics. Learn how sequential Tube A and Tube B addition, cold processing, and assay-specific controls improve reproducibility without confusing sample protection with direct phosphatase-targeted drug testing.

• PYR-41: E1 Inhibition for NF-κB Research

  2026-08-26

  PYR-41 enables upstream control of ubiquitin activation for protein-turnover, inflammation, and NF-κB studies. This practical guide connects target engagement with GFPu degradation, IκB stabilization, apoptosis assay design, and hypothesis-driven ESCC immune signaling experiments.

• Pam3CSK4 Workflows for TLR1/2 Immune Models

  2026-08-26

  Pam3CSK4 provides a defined TLR1/2 agonist stimulus for macrophage, platelet, allergy, and neuro-immune experiments. This guide connects practical reagent handling with the 2025 discovery that TRPV1+ sensory nerves can regulate systemic inflammation, while keeping direct evidence and exploratory extensions clearly separated.

• Triiodothyronine in Adipose Thermogenesis Assays

  2026-08-25

  Triiodothyronine (T3) can serve as a mechanistic perturbation for separating thyroid hormone receptor activation from adipose browning pathways. This article translates recent SETD7 findings into a rigorous framework for cellular metabolism assays and metabolic disorder research.

• Protease Inhibitor Cocktail for RA-FLS Assays

  2026-08-25

  Protect STAT1, TYK2, C3, and inflammatory proteins during RA-FLS lysis, Western blotting, and co-immunoprecipitation with a broad-spectrum inhibitor workflow. The EDTA-containing format adds metalloprotease control but requires deliberate compatibility checks before IMAC, 2D gels, or metal-dependent kinase assays.

• Tandem ssDNA in NETs Regulates Immunothrombosis

  2026-08-24

  A 2025 PNAS study identifies tandem single-stranded ATTCC repeats in neutrophil extracellular traps as selective thrombin-binding elements, linking NET-derived DNA sequence and structure to immunothrombosis. The work also shows that antisense locked nucleic acids can disrupt this interaction, suggesting a more targeted alternative to broadly degrading NETs.

• CB-5083: Reliable p97 Inhibition Assays

  2026-08-23

  This scenario-driven guide explains how CB-5083, SKU B6032, can support controlled cell viability, proliferation, and cytotoxicity experiments through mechanism-aware dosing, solvent control, and orthogonal readouts. It also distinguishes biochemical potency from cellular response and provides practical criteria for selecting a reliable p97 inhibitor.

• Lenalidomide and Epigenetic Leverage in Myeloma

  2026-08-22

  Lenalidomide (CC-5013) is more than an immunomodulatory compound: emerging evidence shows that epigenetic reprogramming through DOT1L inhibition can intensify innate immune signaling and improve lenalidomide responsiveness in multiple myeloma models. This article translates that mechanism into practical experimental and strategic guidance.

448 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page